Article Text

Download PDFPDF
Review: reboxetine is ineffective and potentially harmful for acute treatment of major depression

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Sources of funding Institute for Quality and Efficiency in Health Care, Germany. Project commissioned by the German Federal Joint Committee.


  • Competing interests MAK has received grants or research support from CIHR, Sick Kids Foundation, Centre for Addiction and Mental Health Foundation, Canadian Psychiatric Research Foundation, Canadian Foundation for Innovation, GlaxoSmithKline, Wyeth Pharmaceuticals, Lundbeck Canada, Eli Lilly, Organon, Astra Zeneca, Janssen-Ortho, Solve, Genuine Health, Shire, Bristol-Myers Squib, Boehringer Ingelheim, VNS, Genuine Health, Pfizer, Servier, Sanofi Aventis and Brain Cells (BCI). He has also received speaker honoraria from GlaxoSmithKline, Wyeth Pharmaceuticals, Lundbeck, Eli Lilly, Boehringer Ingelheim, Organon, Astra Zeneca, Janssen-Ortho, Solve, Bristol-Myers Squib, Shire Canada, Canada, Pfizer and Biovail.